CN107337659A - 作为蛋白激酶调节剂的新颖化合物 - Google Patents
作为蛋白激酶调节剂的新颖化合物 Download PDFInfo
- Publication number
- CN107337659A CN107337659A CN201710450892.9A CN201710450892A CN107337659A CN 107337659 A CN107337659 A CN 107337659A CN 201710450892 A CN201710450892 A CN 201710450892A CN 107337659 A CN107337659 A CN 107337659A
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- disease
- compound
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCC(C)=C(C(C(NC)=NC=C)=[*@@]=C(C)N)I Chemical compound CCC(C)=C(C(C(NC)=NC=C)=[*@@]=C(C)N)I 0.000 description 17
- NMBMSXSIGUBXLV-UHFFFAOYSA-N CC(C(Oc1c2c(F)ccc1)=C(c(cccc1)c1F)C2=O)=C Chemical compound CC(C(Oc1c2c(F)ccc1)=C(c(cccc1)c1F)C2=O)=C NMBMSXSIGUBXLV-UHFFFAOYSA-N 0.000 description 1
- IGSSPKPGTCLJBH-SFQUDFHCSA-N CC/C(/C)=C(/C(c1c(C)cccc1F)=O)\c(cccc1)c1F Chemical compound CC/C(/C)=C(/C(c1c(C)cccc1F)=O)\c(cccc1)c1F IGSSPKPGTCLJBH-SFQUDFHCSA-N 0.000 description 1
- NIJGOEAALWMRTH-PHQQDLDCSA-N CC/C=C\C(\C1=C(CC)OC2=CCCC(C)=C2C1=O)=C/C Chemical compound CC/C=C\C(\C1=C(CC)OC2=CCCC(C)=C2C1=O)=C/C NIJGOEAALWMRTH-PHQQDLDCSA-N 0.000 description 1
- FVXFNDTXWSVPRT-UHFFFAOYSA-N CC1(C2C1)C=Cc1c2c(C)n[nH]1 Chemical compound CC1(C2C1)C=Cc1c2c(C)n[nH]1 FVXFNDTXWSVPRT-UHFFFAOYSA-N 0.000 description 1
- GCMQODWZIFKDCT-ZRIYNBNISA-N CCCC(Oc1cccc(F)c1C1O)=C1C1=CC=C[C@H]2C1=C2C Chemical compound CCCC(Oc1cccc(F)c1C1O)=C1C1=CC=C[C@H]2C1=C2C GCMQODWZIFKDCT-ZRIYNBNISA-N 0.000 description 1
- GZDHLMWPCKBQTQ-UHFFFAOYSA-N CN(C)C1=NCN(C)c2c1c(I)n[nH]2 Chemical compound CN(C)C1=NCN(C)c2c1c(I)n[nH]2 GZDHLMWPCKBQTQ-UHFFFAOYSA-N 0.000 description 1
- RHIWCVREVUOMBP-ZGVWCRDDSA-N C[C@@H](C/C=C(\C)/NC(CCC1=CCCC=C1C)C(C)=O)CC(C)=O Chemical compound C[C@@H](C/C=C(\C)/NC(CCC1=CCCC=C1C)C(C)=O)CC(C)=O RHIWCVREVUOMBP-ZGVWCRDDSA-N 0.000 description 1
- ORRKNDNHEAONIX-URGPSIQFSA-N C[C@@H](COC1C(/C=C\C(CCCCC(C2C(F)=CC=CC2)=C)F)=C1C)O Chemical compound C[C@@H](COC1C(/C=C\C(CCCCC(C2C(F)=CC=CC2)=C)F)=C1C)O ORRKNDNHEAONIX-URGPSIQFSA-N 0.000 description 1
- XCBYYXLOEBELSB-UHFFFAOYSA-N Cc1ccc(CN)[s]1 Chemical compound Cc1ccc(CN)[s]1 XCBYYXLOEBELSB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1542CH2011 | 2011-05-04 | ||
IN1542/CHE/2011 | 2011-05-04 | ||
IN81CH2012 | 2012-01-09 | ||
IN81/CHE/2012 | 2012-01-09 | ||
CN201280031627.2A CN103702989B (zh) | 2011-05-04 | 2012-05-04 | 作为蛋白激酶调节剂的新颖化合物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280031627.2A Division CN103702989B (zh) | 2011-05-04 | 2012-05-04 | 作为蛋白激酶调节剂的新颖化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107337659A true CN107337659A (zh) | 2017-11-10 |
Family
ID=46147717
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710450892.9A Pending CN107337659A (zh) | 2011-05-04 | 2012-05-04 | 作为蛋白激酶调节剂的新颖化合物 |
CN201280031627.2A Active CN103702989B (zh) | 2011-05-04 | 2012-05-04 | 作为蛋白激酶调节剂的新颖化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280031627.2A Active CN103702989B (zh) | 2011-05-04 | 2012-05-04 | 作为蛋白激酶调节剂的新颖化合物 |
Country Status (27)
Country | Link |
---|---|
US (5) | US9775841B2 (ja) |
EP (1) | EP2705029B1 (ja) |
JP (2) | JP6118314B2 (ja) |
KR (1) | KR101992311B1 (ja) |
CN (2) | CN107337659A (ja) |
AP (1) | AP4075A (ja) |
AU (1) | AU2012250576B2 (ja) |
BR (1) | BR112013027774B1 (ja) |
CA (1) | CA2833935C (ja) |
CL (1) | CL2013003160A1 (ja) |
CO (1) | CO6852069A2 (ja) |
CY (1) | CY1121170T1 (ja) |
DK (1) | DK2705029T3 (ja) |
EA (1) | EA024842B9 (ja) |
ES (1) | ES2710874T3 (ja) |
HR (1) | HRP20190128T1 (ja) |
HU (1) | HUE042322T2 (ja) |
LT (1) | LT2705029T (ja) |
MX (1) | MX365160B (ja) |
MY (1) | MY168757A (ja) |
PL (1) | PL2705029T3 (ja) |
PT (1) | PT2705029T (ja) |
RS (1) | RS58326B1 (ja) |
SG (1) | SG194718A1 (ja) |
SI (1) | SI2705029T1 (ja) |
WO (1) | WO2012151525A1 (ja) |
ZA (1) | ZA201307964B (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3022722A1 (en) | 2009-11-05 | 2011-05-12 | Rhizen Pharmaceuticals S.A. | Pi3k protein kinase modulators |
JP6118314B2 (ja) | 2011-05-04 | 2017-04-19 | ライゼン・ファーマシューティカルズ・エスアー | タンパク質キナーゼのモジュレーターとしての新規化合物 |
CA2868026C (en) * | 2012-03-23 | 2021-02-16 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
CA2871000C (en) * | 2012-05-04 | 2021-10-19 | Rhizen Pharmaceuticals Sa | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals |
US10130635B2 (en) | 2012-05-04 | 2018-11-20 | Rhizen Pharmaceuticals Sa | Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals |
EP2870157B1 (en) * | 2012-07-04 | 2017-08-30 | Rhizen Pharmaceuticals S.A. | Selective pi3k delta inhibitors |
EP2916868B1 (en) | 2012-11-08 | 2022-05-11 | Rhizen Pharmaceuticals S.A. | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
NO3004106T3 (ja) * | 2013-06-07 | 2018-01-27 | ||
EP3016955B1 (en) | 2013-07-02 | 2018-03-07 | Rhizen Pharmaceuticals S.A. | Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors |
TWI672297B (zh) | 2013-12-18 | 2019-09-21 | 義大利商吉斯藥品公司 | 作為磷脂肌醇-3-激酶抑制劑之異唏衍生物 |
SG11201610745XA (en) * | 2014-06-27 | 2017-01-27 | Rhizen Pharmaceuticals Sa | Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases |
WO2016011394A1 (en) * | 2014-07-18 | 2016-01-21 | The General Hospital Corporation | Imaging agents for neural flux |
EA038527B1 (ru) * | 2014-09-03 | 2021-09-10 | Ризен Фармасьютикалз Са | Способ лечения респираторного заболевания или состояния, композиции и наборы, содержащие двойной ингибитор киназ pi3k дельта-гамма и кортикостероид |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN104610331A (zh) * | 2015-02-26 | 2015-05-13 | 成都安斯利生物医药有限公司 | 4-(1,3-恶嗪-2-基)苯硼酸的制备方法 |
CN106008479B (zh) * | 2015-03-06 | 2020-01-10 | 南京圣和药业股份有限公司 | 作为磷脂酰肌醇3-激酶δ抑制剂的取代嘧啶类化合物及其应用 |
CN105936635B (zh) * | 2015-03-06 | 2019-06-21 | 南京圣和药业股份有限公司 | 作为磷脂酰肌醇3-激酶δ抑制剂的化合物及其应用 |
US9968604B2 (en) * | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
EP3328839A1 (en) * | 2015-07-30 | 2018-06-06 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP4194459A1 (en) * | 2016-06-20 | 2023-06-14 | Shionogi & Co., Ltd | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
CN106831636A (zh) * | 2016-12-12 | 2017-06-13 | 湖南华腾制药有限公司 | 一种恶二唑化合物的制备方法 |
JP7200126B2 (ja) * | 2017-04-05 | 2023-01-06 | キュロヴィル・アクチボラグ | 療法において有用なヘテロ芳香族化合物 |
CN107652261B (zh) * | 2017-09-30 | 2020-08-07 | 桂林医学院 | 一种毛蕊异黄酮衍生物及其合成方法 |
AU2019209960B2 (en) | 2018-01-20 | 2023-11-23 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
WO2021108483A1 (en) * | 2019-11-27 | 2021-06-03 | Genentech, Inc. | Therapeutic compounds |
KR20210099402A (ko) * | 2020-02-04 | 2021-08-12 | 고려대학교 산학협력단 | 펜벤다졸, 옥시벤다졸 또는 이들의 혼합물을 포함하는 자궁내막 세포 또는 영양막 세포의 비정상적 증식 관련 질환의 예방 또는 치료용 약학적 조성물 |
CA3182911A1 (en) * | 2020-05-11 | 2021-11-18 | Talengen International Limited | Method and drug for treating spinal muscular atrophy |
EP4149629A1 (en) | 2020-05-14 | 2023-03-22 | Rhizen Pharmaceuticals AG | Purine derivatives as sik-3 inhibitors |
WO2022063101A1 (zh) * | 2020-09-23 | 2022-03-31 | 劲方医药科技(上海)有限公司 | 芳甲酰取代的三环化合物及其制法和用途 |
WO2023123742A1 (zh) * | 2021-12-31 | 2023-07-06 | 同润生物医药(上海)有限公司 | PI3Kδ/γ双重抑制剂化合物的半富马酸盐结晶及其制备方法 |
CN114891005B (zh) * | 2022-03-30 | 2024-01-19 | 武汉九州钰民医药科技有限公司 | 一种乌帕利斯对甲苯磺酸盐的制备工艺 |
KR102616744B1 (ko) * | 2023-04-10 | 2023-12-27 | 한국교통대학교산학협력단 | 발효 자몽추출물을 포함하는 장 건강 개선용 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4841077A (en) * | 1985-11-18 | 1989-06-20 | Yamanouchi Pharmaceutical Co., Ltd. | Isoflavone derivatives, and salts thereof, and cancerocidal and immunosuppressive agents containing the same |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
FR2224144B1 (ja) * | 1973-04-06 | 1976-04-09 | Rech Pharmaceutiq Scientif | |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
JP2876058B2 (ja) | 1986-08-18 | 1999-03-31 | エミスフィア・テクノロジーズ・インコーポレイテッド | 薬物送達システム |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
ATE156158T1 (de) | 1992-04-14 | 1997-08-15 | Cornell Res Foundation Inc | Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung |
US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
JPH08175990A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Pi3キナーゼ阻害剤とその製造法 |
JPH08176070A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | ジデプシド誘導体及びpi3キナーゼ阻害剤 |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
JP3053222B2 (ja) | 1995-04-20 | 2000-06-19 | ファイザー・インコーポレーテッド | Mmpおよびtnf抑制剤としてのアリールスルホニルヒドロキサム酸誘導体 |
GB9521987D0 (en) | 1995-10-26 | 1996-01-03 | Ludwig Inst Cancer Res | Phosphoinositide 3-kinase modulators |
ES2183905T3 (es) | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer Inc., New York | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
IL128189A0 (en) | 1996-08-23 | 1999-11-30 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
EP0950059B1 (en) | 1997-01-06 | 2004-08-04 | Pfizer Inc. | Cyclic sulfone derivatives |
ID22799A (id) | 1997-02-03 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan asam arilsulfonilamino hidroksamat |
BR9807824A (pt) | 1997-02-07 | 2000-03-08 | Pfizer | Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz |
ID22809A (id) | 1997-02-11 | 1999-12-09 | Pfizer | Turunan-turunan asam arilsulfonil hidroksamat |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PL212545B1 (pl) | 1999-02-22 | 2012-10-31 | Biotechnolog Forschung Gmbh | Modyfikowane epofilony C-21 o wzorze Ia lub Ib oraz sposób wytwarzania zwiazku o wzorze 9 |
JP2001247477A (ja) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | 抗腫瘍剤 |
ES2527754T3 (es) | 2000-04-25 | 2015-01-29 | Icos Corporation | Inhibidores de la isoforma delta de la fosfatidilinositol 3-quinasa humana |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
US7141576B2 (en) | 2001-01-16 | 2006-11-28 | Smithkline Beecham (Cork) Limited | Cancer treatment method |
EP1417976A4 (en) | 2001-07-26 | 2004-09-15 | Santen Pharmaceutical Co Ltd | AGENT FOR TREATING GLAUKOM WITH A COMPOUND WITH PI3-KINASE INHIBITING EFFECT |
US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
AU2002349912A1 (en) | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
AU2002357667A1 (en) | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
JP2005509645A (ja) | 2001-10-30 | 2005-04-14 | ファルマシア・コーポレーション | 炎症処置用のヘテロ芳香族カルボキサミド誘導体 |
MXPA04010240A (es) * | 2002-04-17 | 2005-06-08 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
CA2493843C (en) | 2002-07-10 | 2012-04-17 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused-benzene derivatives |
JP2006500327A (ja) | 2002-07-10 | 2006-01-05 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 精子の運動性を増大させるための化合物の使用 |
AU2003255845A1 (en) | 2002-08-22 | 2004-03-11 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
US7601724B2 (en) | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7605155B2 (en) | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
DE10256174A1 (de) * | 2002-12-02 | 2004-06-09 | Merck Patent Gmbh | 2-Benzoylchromonderivate |
WO2004072029A2 (en) | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
GB0305152D0 (en) * | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
EP1631548B1 (en) | 2003-04-24 | 2009-10-28 | Merck & Co., Inc. | Inhibitors of akt activity |
EP1663211B1 (en) | 2003-08-06 | 2010-01-20 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
AU2004296868B2 (en) * | 2003-12-09 | 2010-11-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for suppressing an immune response or treating a proliferative disorder |
PT3153514T (pt) * | 2004-05-13 | 2021-06-25 | Icos Corp | Quinazolinonas como inibidoras da fosfatidilinositol 3-quinase delta humana |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
CN101065016A (zh) | 2004-09-24 | 2007-10-31 | 詹森药业有限公司 | 蛋白激酶的抑制剂咪唑并[4,5-b]吡嗪酮 |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
FR2882751B1 (fr) | 2005-03-04 | 2007-09-14 | Aventis Pharma Sa | Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, procede de preparation, compositions les contenant et utilisation |
CA2612841A1 (en) | 2005-07-08 | 2007-01-18 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
JP5016601B2 (ja) | 2005-08-16 | 2012-09-05 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
PE20070518A1 (es) | 2005-09-06 | 2007-06-12 | Smithkline Beecham Corp | Compuestos de tiofeno bencimidazol como agentes inhibidores de plk |
JP5461012B2 (ja) | 2005-10-07 | 2014-04-02 | エクセリクシス, インク. | PI3Kαのピリドピリミジノン型阻害剤 |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
CA2624676A1 (en) | 2005-10-21 | 2007-05-03 | Jongwon Lim | Tyrosine kinase inhibitors |
EP1981884B1 (en) | 2006-01-18 | 2012-06-13 | Amgen, Inc | Thiazole compounds as protein kinase b (pkb) inhibitors |
WO2007099317A1 (en) | 2006-03-02 | 2007-09-07 | Astrazeneca Ab | Quinazoline derivatives |
EP2007373A4 (en) | 2006-03-29 | 2012-12-19 | Foldrx Pharmaceuticals Inc | INHIBITION OF ALPHA SYNUCLEINE TOXICITY |
US20090247554A1 (en) | 2006-03-30 | 2009-10-01 | Takeda San Diego, Inc. | Kinase inhibitors |
PT2004654E (pt) * | 2006-04-04 | 2013-08-27 | Univ California | Derivados de pirazolopirimidina para utilização como antagonistas da quinase |
ES2347187T3 (es) | 2006-04-26 | 2010-10-26 | F. Hoffmann-La Roche Ag | Derivado de tieno(3,2-d)pirimidina, util como un inhibidor de pi3k. |
MX2008013583A (es) | 2006-04-26 | 2008-10-31 | Genentech Inc | Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen. |
JPWO2007132867A1 (ja) | 2006-05-15 | 2009-09-24 | 杉本 芳一 | 癌の予防及び治療剤 |
GB0610243D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
JP2009543768A (ja) | 2006-07-14 | 2009-12-10 | アステックス・セラピューティクス・リミテッド | 医薬組み合わせ |
WO2008021859A1 (en) | 2006-08-09 | 2008-02-21 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
CN101563340A (zh) | 2006-09-14 | 2009-10-21 | 阿斯利康(瑞典)有限公司 | 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物 |
EP2441768A1 (en) | 2006-11-13 | 2012-04-18 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
BRPI0717923A2 (pt) | 2006-12-07 | 2013-10-22 | Genentech In | '' composto, composição farmacêutica, método para tratar um câncer, processo para a produção de uma composição farmacêutica, usos, métodos para inibir ou modular a atividade da lipídeo quinase e kit ' ' |
EP2114950B1 (en) | 2006-12-07 | 2016-03-09 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
JP2010522177A (ja) | 2007-03-23 | 2010-07-01 | アムジエン・インコーポレーテツド | 複素環化合物およびその使用 |
CL2008001356A1 (es) | 2007-05-10 | 2008-11-14 | Smithkline Beecham Corp | Compuestos derivados de quinoxalina, inhibidores de la pi3 quinasa _(p13ka, pi3ko, pi3b y/o pi3ky); composicion farmaceutica; uso para tratar un trastorno autoinmune, enfermedad inflamatoria, cardiovascular, neurodegerativa, alergia, asma, enfermedad renal, cancer, rechazo de transplante, lesiones pulmonares. |
US20090263397A1 (en) | 2007-07-06 | 2009-10-22 | Buck Elizabeth A | Combination anti-cancer therapy |
MY159955A (en) | 2008-01-04 | 2017-02-15 | Intellikine Inc | Certain chemical entities, compositions and methods |
KR101216323B1 (ko) | 2008-02-22 | 2012-12-27 | 아이알엠 엘엘씨 | C?kit 및 pdgfr 키나제 억제제로서의 헤테로시클릭 화합물 및 조성물 |
CN102036561A (zh) | 2008-02-29 | 2011-04-27 | 赛林药物股份有限公司 | 蛋白激酶调节剂 |
NZ587518A (en) | 2008-03-04 | 2012-09-28 | Natco Pharma Ltd | Crystalline form III of (3,5-bis trifluoromethyl)-N-[4-methyl-3-({ 4-(pyridin-3 yl)-pyrimidin-2-yl} amino)-phenyl]-benzamide |
WO2009111547A1 (en) | 2008-03-04 | 2009-09-11 | Wyeth | 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
CN102015719A (zh) | 2008-03-06 | 2011-04-13 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
UY31700A (es) | 2008-03-13 | 2009-11-10 | Boehringer Ingelheim Int | Tiazolil-dihidro-indazoles |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
WO2009114870A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
MX2010010300A (es) | 2008-03-19 | 2010-10-26 | Osi Pharm Inc | Formas de sal de inhibidores del objetivo de rapamicina en mamiferos. |
WO2009117097A1 (en) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Novel tyrosine kinase inhibitors |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
US20110053907A1 (en) | 2008-03-27 | 2011-03-03 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
US7928248B2 (en) | 2008-03-31 | 2011-04-19 | Genentech, Inc. | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use |
US20090258907A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | Compounds useful as inhibitors of rock kinases |
EP2297145A2 (en) | 2008-04-16 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n- (1-methylpiperidin-4-yl)-9h-pyrido[2, 3-b]indole-7-carboxamide and methods of use therefor |
AU2009236380A1 (en) | 2008-04-16 | 2009-10-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
DK2358720T3 (en) | 2008-10-16 | 2016-06-06 | Univ California | Heteroarylkinaseinhibitorer fused-ring |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010059593A1 (en) | 2008-11-18 | 2010-05-27 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
AR077267A1 (es) * | 2009-06-25 | 2011-08-17 | Amgen Inc | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. |
CA3022722A1 (en) * | 2009-11-05 | 2011-05-12 | Rhizen Pharmaceuticals S.A. | Pi3k protein kinase modulators |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
JP6118314B2 (ja) * | 2011-05-04 | 2017-04-19 | ライゼン・ファーマシューティカルズ・エスアー | タンパク質キナーゼのモジュレーターとしての新規化合物 |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
EP2870157B1 (en) * | 2012-07-04 | 2017-08-30 | Rhizen Pharmaceuticals S.A. | Selective pi3k delta inhibitors |
WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
US20140120060A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors |
DK2914296T4 (da) | 2012-11-01 | 2022-01-03 | Infinity Pharmaceuticals Inc | Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer |
EP2916868B1 (en) * | 2012-11-08 | 2022-05-11 | Rhizen Pharmaceuticals S.A. | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
-
2012
- 2012-05-04 JP JP2014509494A patent/JP6118314B2/ja active Active
- 2012-05-04 ES ES12722989T patent/ES2710874T3/es active Active
- 2012-05-04 EP EP12722989.6A patent/EP2705029B1/en active Active
- 2012-05-04 KR KR1020137032130A patent/KR101992311B1/ko active IP Right Grant
- 2012-05-04 AP AP2013007225A patent/AP4075A/en active
- 2012-05-04 LT LTEP12722989.6T patent/LT2705029T/lt unknown
- 2012-05-04 MY MYPI2013003965A patent/MY168757A/en unknown
- 2012-05-04 PT PT12722989T patent/PT2705029T/pt unknown
- 2012-05-04 SI SI201231512T patent/SI2705029T1/sl unknown
- 2012-05-04 US US13/464,587 patent/US9775841B2/en active Active
- 2012-05-04 WO PCT/US2012/036594 patent/WO2012151525A1/en active Application Filing
- 2012-05-04 CN CN201710450892.9A patent/CN107337659A/zh active Pending
- 2012-05-04 PL PL12722989T patent/PL2705029T3/pl unknown
- 2012-05-04 CN CN201280031627.2A patent/CN103702989B/zh active Active
- 2012-05-04 CA CA2833935A patent/CA2833935C/en active Active
- 2012-05-04 SG SG2013080726A patent/SG194718A1/en unknown
- 2012-05-04 EA EA201391416A patent/EA024842B9/ru unknown
- 2012-05-04 HU HUE12722989A patent/HUE042322T2/hu unknown
- 2012-05-04 DK DK12722989.6T patent/DK2705029T3/en active
- 2012-05-04 AU AU2012250576A patent/AU2012250576B2/en not_active Ceased
- 2012-05-04 MX MX2013012896A patent/MX365160B/es active IP Right Grant
- 2012-05-04 BR BR112013027774-2A patent/BR112013027774B1/pt not_active IP Right Cessation
- 2012-05-04 RS RS20190098A patent/RS58326B1/sr unknown
-
2013
- 2013-10-24 ZA ZA2013/07964A patent/ZA201307964B/en unknown
- 2013-11-04 CL CL2013003160A patent/CL2013003160A1/es unknown
- 2013-12-03 CO CO13283837A patent/CO6852069A2/es active IP Right Grant
-
2015
- 2015-06-25 US US14/750,953 patent/US10220035B2/en active Active
-
2017
- 2017-03-24 JP JP2017058876A patent/JP2017119708A/ja active Pending
- 2017-08-15 US US15/677,614 patent/US10322130B2/en active Active
-
2019
- 2019-01-21 CY CY20191100080T patent/CY1121170T1/el unknown
- 2019-01-21 HR HRP20190128TT patent/HRP20190128T1/hr unknown
- 2019-03-20 US US16/359,419 patent/US11020399B2/en active Active
-
2021
- 2021-04-15 US US17/301,841 patent/US20210401840A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4841077A (en) * | 1985-11-18 | 1989-06-20 | Yamanouchi Pharmaceutical Co., Ltd. | Isoflavone derivatives, and salts thereof, and cancerocidal and immunosuppressive agents containing the same |
Non-Patent Citations (3)
Title |
---|
G. ELENA DAIA ET AL.,: "Synthesis and cycloadditions of 9H-furo[3,4-b][1]benzo(thio)pyran-9-ones: furan ring formation by a novel hydrolytically induced cycloreversion", 《TETRAHEDRON LETTERS》 * |
MANMEET KUMAR ET AL.,: "One step synthesis of 2-hydroxymethylisoflavone and their osteogenic activity", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
PAOLO COZZI ET AL.,: "Imidazolyl derivatives of the chroman ring,2[1]", 《J.HETEROCYCLIC CHEM.》 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103702989B (zh) | 作为蛋白激酶调节剂的新颖化合物 | |
CN102812013B (zh) | 新型苯并吡喃激酶调节剂 | |
CN103068824B (zh) | 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物 | |
CN104321322A (zh) | 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物 | |
NZ616834B2 (en) | Novel compounds as modulators of protein kinases | |
EA039266B1 (ru) | Производные 4н-хромен-4-она в качестве модуляторов протеинкиназ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |